Sanofi-Aventis Nominates Le Fur For CEO Post In 2007
This article was originally published in The Pink Sheet Daily
Under the proposal, Sanofi-Aventis CEO Dehecq will remain as chairman for three years to ensure a smooth transition.
You may also be interested in...
Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.
Sanofi-Aventis' $30 bil. pharma/vaccine business will provide bulk necessary to better negotiate discounts. Sanofi has not had much opportunity to work within U.S. managed care system, but says it will learn from Aventis.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.